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A B S T R A C T
Metabolic Syndrome (MS) is characterized by dysglycemia, arterial hypertension, 
atherogenic dyslipidemia and central obesity. Its presence has been associated with 
increased risk for the development of diabetes mellitus and cardiovascular disease. 
The main treatment goal is to lower the incidence of both MS and its cardiovascular 
sequelae and includes diet, exercise, weight loss, control of blood glucose and phar-
macological therapy of hypertension and dyslipidemia. Nursing care focuses in the 
development of a concise treatment plan based upon patient’s education, psychosocial 
support and close follow-up. Nurses should have a wide knowledge of MS pathophysi-
ology which will facilitate their active participation in both diagnosis and treatment 
processes. The final goal is to assure the long-term compliance of patients with both 
the proposed lifestyle changes and the medical treatment in order to achieve a signifi-
cant reduction in their cardiovascular morbidity and mortality.
I N T R O D U C T I O N  -  H I S T O R Y
The clustering of cardiovascular risk factors like obesity, type 2 diabetes, hyperli-
pidemia and hypertension in the same person was initially described several decades 
ago.1,2 On the other hand, insulin resistance has been the earliest described character-
istic of type 2 diabetes mellitus.3 The association of diabetes with hyperinsulinemia, 
hyperlipidemia, obesity and hypertension were subsequently reported. Thus, it became 
clear that the majority of patients suffering from type 2 diabetes had also high inci-
dence of several other cardiovascular risk factors.4 This risk factor clustering and its 
association with insulin resistance was attributed to a distinct pathophysiologic entity 
named initially as “insulin resistance syndrome”.5,6
Reaven in his hallmark lecture in 19887 unified and expanded these aspects by 
introducing the term “syndrome X” to describe the combination of these cardiovas-
cular risk factors (hypertension, hyperglycemia, dyslipidemia). He developed the 
hypothesis that insulin resistance resulting in compensatory increased insulin plasma 
levels, predisposed to the development of hypertension, hyperlipidemia and diabetes. 
Obesity was not included in Reaven’s list of insulin resistance derived abnormalities 
although he accepted the existence of an association between obesity and insulin 
resistance. Subsequently, other investigators underlined the pivotal role of obesity as 
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a causal factor of Reaven’s syndrome X and used instead the 
term “Metabolic Syndrome” (MS) which finally prevailed in 
the literature and in clinical practice.8
D E F I N I T I O N  A N D  P A T H O P H Y S I O L O G Y 
O F  T H E  M E T A B O L I C  S Y N D R O M E
Metabolic Syndrome is a combination of interrelated 
metabolic abnormalities (metabolic risk factors) that increase 
the risk of atherosclerotic cardiovascular disease. Patients 
with MS are prone to the development of diabetes mellitus 
type 2, coronary artery disease and cerebrovascular disease. 
Another cluster of pathophysiologic conditions (underlying 
risk factors) are thought to be the cause of the metabolic risk 
factors. Dyslipidemia, high blood pressure and high blood 
glucose are the principal metabolic risk factors. Patients with 
these abnormalities are also frequently in a pro-thrombotic 
and pro-inflammatory state.9-11
The most important underlying risk factors are central 
obesity and insulin resistance, whereas associated conditions 
are sedentary life, age and hormonal abnormalities leading 
to increased androgen production (e.g. polycystic ovary syn-
drome) (Fig. 1).12-14 Although the cause of MS has not been 
clearly defined, most experts agree that insulin resistance is 
the primary underlying abnormality.15 Insulin resistance is re-
sponsible for the hyperglycemia observed in diabetes mellitus. 
Multiple metabolic pathways have been proposed as the link 
between insulin resistance, compensatory hyperinsulinemia 
and the other metabolic risk factors.16 On the other hand, 
insulin resistance is closely related to the development of ab-
dominal or central obesity which is thought to be responsible 
for the increased prevalence of the MS noted during the last 
few years. Individuals with insulin resistance are not necessar-
ily overweight. They exhibit however an abnormal distribution 
of adipose tissue mainly in the upper part of their body (central 
obesity).17 This type of obesity highly correlates with insulin 
resistance.18 Interestingly, upper body fat distribution leads 
to an increased release of non-esterified fatty acids from the 
adipose tissue in the circulation which subsequently accumu-
late in other tissues.19,20 This ectopic fat accumulation into the 
muscles21 and the liver22 –the two main target organs of insu-
lin- predispose to insulin resistance. Moreover, the abnormal 
production of fatty tissue hormones (adipokines) also affect 
insulin sensitivity and modifies atherosclerosis risk factors like 
inflammatory cytokines and tissue plasminogen activator in-
hibitor.23,24 Based on these findings some investigators believe 
that a low-grade inflammation may be either the underlying 
cause or simply the aggravating factor of the MS.25,26 Finally 
some genetic predisposition to the development of the MS is 
also thought to exist. This genetic background seems to influ-
ence the phenotypic expression of the syndrome after exposure 
in different environments. This seems to explain the ethnic 
variations in the clinical expression of metabolic risk factors 
in obese individuals with insulin resistance.27
Several terms, other than MS, have been proposed in the 
literature, such as Dysmetabolic or Polymetabolic Syndrome, 
Insulin Resistance Syndrome, or Syndrome X. Three defini-
tions of the MS are currently in common use. According to 
the World Health Organization’s (WHO)28 diagnostic criteria, 
dysglycemia (diabetes, glucose intolerance) along with two of 
the following, increased body mass index (BMI), dyslipidemia, 
high blood pressure and microalbuminuria, are required to 
define the MS (Fig. 2). The National Cholesterol Education 
Program Adult Treatment Program III (NCEP ATP III)29 cri-
teria are more suitable for clinical use although based upon the 
same principle (Fig. 3). At least three of the following criteria 
FIGURE 1. Metabolic risk factors and their underlying abnor-
malities in the metabolic syndrome.
FIGURE 2. Definition of the metabolic syndrome (MS) accord-
ing to the World Health Organization (WHO) criteria.
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have to be present: central obesity, dyslipidemia, hypertension, 
and fasting glucose ≥110 mg/dl. In the most recent definition 
of MS published by the International Diabetes Federation 
(IDF)30 (Figure 4), fasting glucose cut-off point have been 
lowered to 100 mg/dl. Central obesity in addition to two of the 
other classic criteria is required for the diagnosis.
M E T A B O L I C  S Y N D R O M E  A N D 
C A R D I O V A S C U L A R  R I S K  –  P R E V A L E N C E 
O F  T H E  M E T A B O L I C  S Y N D R O M E
Every single component of the MS increases cardiovas-
cular risk,31-33 while their combination has been associated 
with an exponential increase of cardiovascular morbidity and 
mortality.34-36 Many studies have shown that patients with MS 
have an increased incidence of cardiovascular disease. In these 
studies, the risk excess varies from 30-400%. This high vari-
ability could be attributed to differences in the populations 
studied, in the definition criteria used and in the follow-up 
time. From a pathophysiologic point of view, insulin resistance 
has been related to endothelial dysfunction37 and to a delayed 
clearance of atherogenic lipoproteins in the postprandial 
state38 promoting this way the development of the atheroscle-
rotic plaque. Obesity, on the other hand, has been associated 
with increased production of inflammatory cytokines and 
pro-thrombotic factors9 which promote atherosclerotic plaque 
rupture. Finally, MS has been associated with an increased 
concentration of the highly atherogenic small dense LDL 
cholesterol particles.
The metabolic syndrome is extremely common. According 
to the WHO definition, 25% of the USA adult population 
has the syndrome while 23.9% fit the NCEP ATP III crite-
ria.40 The results of the INTERHEART study, a large trial 
conducted in 52 countries, 26% of the control group had the 
MS.41 Men and black individuals are at higher risk to develop 
the syndrome, the prevalence of which increases also with 
age.40 Based on data form the National Health and Nutrition 
Examination Survey (NHANES) the prevalence of the MS 
is 6.7% in persons less than 30 years old but goes up to 40% 
in those older than 60 years.40
D I A G N O S I S - P R E V E N T I O N - T R E A T M E N T 
O F  T H E  M E T A B O L I C  S Y N D R O M E :  T H E 
N U R S E ’ S  R O L E
Given the high prevalence of the MS (approximately 47 
million in the USA) and its well established relationship with 
the increasing incidence of diabetes mellitus, coronary artery 
disease and stroke, prevention, diagnosis and treatment of this 
poly-metabolic abnormality should become a high priority 
FIGURE 4. Definition of the metabolic syndrome according to 
the International Diabetes Federation (IDF) criteria.FIGURE 3. Definition of the metabolic syndrome according to 
the National Cholesterol Education Program Adult Treatment 
Program III (NCEP ATP III) criteria.
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goal. The coordinated work of various health care profes-
sionals is essential to achieve high success rates in diagnosis 
and treatment. Among these health providers, the nurse has 
a very important role given her or his close relationship with 
the patient and her or his holistic approach to health prob-
lems. This latter approach facilitates the implementation of 
the integrated type of intervention required for “reversing the 
tide” of this major health crisis.
N U R S E ’ S  R O L E  I N  T H E  D I A G N O S I S  
O F  T H E  M E T A B O L I C  S Y N D R O M E
To establish the diagnosis of MS is mandatory to recognize 
its individual components through their clinical characteris-
tics. Obesity is the most important and also the most clinically 
obvious abnormality of the MS. Generalized obesity refers 
to increased weight in relation to an individual’s height and 
can be determined by calculating the body mass index (BMI) 
defined as weight in kilograms divided by height in meters 
square (Kg/m2). This parameter is one of the defining criteria 
according to the WHO’s definition of the MS. It is the nurse’s 
responsibility to accurately measure BMI. However, central 
obesity defined as the excess adipose tissue residing mainly 
in the upper body within the abdominal region, is thought to 
be a better diagnostic indicator of the MS. This index can be 
calculated either as waist to hip circumference ratio or simply 
as waist circumference in centimeters. Individuals with this 
type of obesity even if they do not fulfill any other criteria of 
the MS, have a high risk to develop it in the future. Obtaining 
of a waist circumference measurement with use of a measur-
ing tape, no matter what the patient’s overall body habitus is, 
should be part of the nurse’s clinical routine. These measure-
ments must be based on standard guidelines (Table 1).42
Insulin resistance along with its accompanying hyperin-
sulinemia is the second major pathopysiologic component of 
the MS. Although fasting blood glucose levels may reflect the 
degree of hyperinsulinemia, it should be remembered that 
normal blood glucose levels (<100 mg/dl) do not exclude the 
existence of an insulin resistance state. Thus, even though 
fasting blood glucose should be measured in every patient 
with the clinical suspicion of MS and a history of anti-diabetic 
medication use should always be taken, the nurse must be 
aware that this information is usually not enough. Two other 
clinical signs suggesting hyperinsulinemia must be sought and 
identified. These signs are: acanthosis nigrans and hirsutism.43 
Acanthosis nigrans is characterized by hyperpigmentation , or 
velvety plaques of body folds (back of the neck, axillae, elbows, 
knee etc). The exact etiology of this cutaneous abnormality is 
unknown but is thought to be caused by hyperinsulinemia.
Hirsutism, an excessive growth of hair in locations where 
hair growth is atypical for women and more common for men, 
could be caused by insulin-mediated overstimulation of the 
ovaries to produce androgens. In that case, hirsutism may be 
part of the polycystic ovary syndrome, which is a common 
cause of hyperinsulinemia and is characterized also by men-
strual irregularities, glucose intolerance and alopecia.
Regarding hyperlipidemia, the nurse must be aware of the 
lipid values considered abnormal and used as criteria for the 
diagnosis of the MS (triglycerides ≥150 mg/dl, HDL-choles-
terol ≤40 mg/dl in men and ≤50 mg/dl in women)
Finally, regarding hypertension, although it is unclear how 
it is caused within the MS, we are certain that its simultane-
ous presence even with only one other component of the MS 
significantly increases cardiovascular risk. Blood pressure 
measurements should be part of the initial assessment of every 
patient with the clinical suspicion of the MS. Accurate and 
reproducible measurements of blood pressure are not only 
a medical but a nursing duty as well, and to achieve these 
measurements the use of standard practicing guidelines is 
necessary44 (Table 2). On the other hand, the use of anti-hy-
pertensive medications confirms the diagnosis of hyperten-
sion without any further assessment and such a history must 
always be obtained.
TABLE 1. Guidelines for accurate patient’s waist measure-
ment
Nursing Guidelines for Waist Measurement
First have the patient face away from you and put his hands at the 
top of his hip bones or iliac crests. Mark this spot on each of his 
hip with a felt-tip pen
Put the measuring tape around your patient at the level of the 
iliac crest
Make sure that the measuring tape is parallel to the floor and that 
it is snug but not so tight that dents the skin
Wait until the patient exhales normally, then take the measure-
ment and record it
TABLE 2. Guidelines for accurate patient’s blood pressure 
measurement
Nursing Guidelines for Blood Pressure Measurement
Make sure that the patient hasn’t had any caffeine or tobacco in 
the past 30 minutes 
Place the patient in a comfortable sitting or lying position for at 
least 5 minutes prior to blood pressure measurement
Choose an appropriate size cuff (it should cover two-thirds of the 
area between his axilla and elbow, and 80% of the bladder should 
encircle his arm
Take one reading , then another 2 minutes later. If the pressure 
differ by 5 mmHg or more, take additional readings at least 2 min-
utes apart and record the average
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N U R S E ’ S  R O L E  I N  T H E  P R E V E N T I O N  A N D 
T R E A T M E N T  O F  T H E  M E T A B O L I C  S Y N D R O M E
The final step after identifying somebody being at risk 
for the development of MS, is to implement measures for 
preventing its full clinical expression while at a later stage in a 
patient who has the MS, health care providers should treat all 
its metabolic abnormalities. The final goal is common in both 
situations: cardiovascular risk reduction. At any stage, patient 
management requires an integrated approach with the involve-
ment of various health care provides, i.e. physicians, nurses, 
dietitians, pharmacists and social workers. Among them the 
nurse plays a pivotal role in implementing a patient-oriented 
therapeutic strategy with realistic goals and expectations. 
Cornerstones of therapy include 1) lifestyle modifications, 2) 
judicious pharmacologic management, and 3) collaborative 
provider/patient partnership aiming at patient’s active par-
ticipation in the achievement of the final goal.45
Lifestyle modification is the most important but also the 
most difficult to achieve and sustain. It has two basic compo-
nents: dietary changes46 and regular exersise.47 Both diet and 
exercise have a beneficial effect on all the abnormalities of 
the MS and especially on obesity. Obese patients should be 
encouraged to lose weight to achieve and sustain a BMI <25 
kg/m2. This can be done by restricting daily calorie intake (to 
1200 calories for women and 1600 calories for men), reducing 
saturated fat in the meals and by engaging in a regular aerobic 
exercise program for 30 minutes daily, 5 days a week. Beyond 
obesity treatment, lifestyle modifications have been proven 
to prevent the development of diabetes and cardiovascular 
disease. Moreover, its contribution to the prevention of MS 
in adult life by reducing the childhood obesity rates seems 
to be of critical importance.48 Lifestyle modifications con-
tribute also to the dyslipidemia and hypertension treatment. 
Dietary guidelines suggest: total cholesterol intake less than 
200 mg/day; fat intake 25% to 35% of total calories per day; 
saturated fats less than 7% of total fat intake; and soluble fiber 
20 to 30 grams/day. Restricting carbohydrate intake to 45% to 
50% of total daily caloric requirements can also help patients 
achieve the goal of lowering triglyceride levels. Trans-fatty 
acids should be less than 2% of total calories since a higher 
intake has been associated with increased LDL cholesterol 
levels. Finally, salt intake should be restricted to 2-4 g/day49 
(Table 3). Finally, enrollment in a smoking-cessation program 
is essential. Nicotine is a potent vasoconstrictor and has been 
identified as the primary cause of heart disease.
Pharmacological therapy is required for patients who are 
unable to achieve target levels of metabolic and blood pres-
sure parameters with lifestyle changes alone. For dyslipidemia 
treatment statins are the drugs of choice.50 Even though they 
do have a major impact upon triglyceride and HDL cholesterol 
levels they have been shown to decrease LDL cholesterol levels 
substantially. Of note, high LDL cholesterol significantly in-
creases cardiovascular risk in patients with MS and reduction 
to <70 mg/dl has been proposed for these patients. Statins can 
be administered concomitantly with fibric acid derivatives, 
nicotinic acid, bile acid sequestrants or ezetimibe to effectively 
reduce all lipid parameters. The statin dosage should be re-
duced, however, when combined with fibric acid derivatives, 
to avoid the potential complication of rabdomyolysis.
Treatment of hypertension is also a very important compo-
nent of the treatment strategy. All classes of antihypertensive 
medications can be used. However, some of those seem 
more appropriate for the patients with MS. For example, 
angiotensin-converting enzyme inhibitors and angiotensin-
receptor blockers are effective in blood pressure management 
without affecting carbohydrate metabolism or aggravating 
lipid levels. They have been found to maintain renal function 
and are renal protective. Moreover, studies have shown that 
they prevent diabetes development in 23% of the patients.51
Regarding hyperglycemia treatment, it has been shown 
that its aggressive management reduces cardiovascular risk 
by approximately 20%.52 Patients with MS are by definition 
insulin-resistant and may benefit from the administration of 
a new category of hypoglycemic agents, thiazolidinediones. 
These drugs, rosiglitazone and pioglitazone, are essentialy 
insulin sensitizers since they work at the cellular level to in-
crease insulin recognition by the receptors. Thiazolidinedi-
ones along with some older antidiabetic medications, acarboze 
and metformin, may also prevent the development of diabetes 
in patients with MS.53
Complementary pharmacological and non-pharmacologi-
cal measures include the administration of low-dose aspirin 
(81-325 mg/day) in men >45 years old and in postmenopausal 
TABLE 3. Lifestyle modification guidelines for the patients 
with Metabolic Syndrome
Nutrient Recommended Intake
Saturated fat <7% of total calories
Polyunsaturated fat Up to 10% of total calories
Monounsaturated fat Up to 20% of total calories
Trans-polyunsaturated fat <2% of total calories
Total fat 25-35% of total calories
Carbohydrate 50-60% of total calories
Proteins 15% of total calories
Fiber 20-30 g/day
Cholesterol <200 mg/day
Total calories Balance energy intake and ex-
penditure to maintain desirable body 
weight / prevent weight gain
Salt 2-4 g /day
Weight Loss to the Desirable Level
Exercise
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women. Folic acid and vitamin B6 decrease homocysteine 
levels and are also beneficial to cardiovascular health of 
these patients. Garlic may reduce total cholesterol by 5% to 
10% in patients with moderately elevated cholesterol (around 
220 mg/dl). The recommendation is to eat 7 grams of garlic 
(a few cloves) per day. Large doses of omega-3 fatty acids (6 
grams/day) may lower total cholesterol and triglyceride levels. 
Fish oil supplements are acceptable, but eating fish, such as 
cold water salmon, daily is preferred.54
For all the above lifestyle modifications and pharmaco-
logical interventions to have a high success rate, the patient 
himself has to become an active participant of his treatment 
plan. Several studies have clearly shown that a very low per-
centge of patients with MS achieve their treatment goals. In 
the United Kingdom Prospective Diabetes Study (UKPDS), 
the propotion of patients achieving the target of glycocylated 
hemoglobin HbA1c <7% after 9 years of follow –up was low 
(ranging from 9 to 18% depending upon treatment group).55 
The situation is similar in the USA. The third National Health 
and Nutrition Examination Survey (NHANES III) showed 
that only half of the hypertensive and another half of the hy-
perlipidemic patients were well controlled. Of great concern, 
fewer than 3.6% of the patients with both hypertension and 
dyslipidemia were at both therapeutic goals.56
This huge gap between “what we know and what we have 
to do” for the MS can be attributed at least partially to the 
following patient barriers:
Lack of awareness and understanding of the problem
Low level of compliance due to medication adverse effects 
or due to reluctance to take life-long treatment
Lack of adherence to lifestyle modifications
Dealing with this major limitation, nursing intervention 
can be of great importance. Basic aspects of this type of 
intervention are:
Patient education in understanding the increased cardio-
vascular risk associated with the MS and the contribution 
of the various treatment modalities in risk reduction.
Psychosocial support of the patient encouraging compli-
ance with diet changes, with increased physical activity 
and with any other risk factor modifications
Support of the patient’s family, encouraging their active 
involvement in the implementation of a successful treat-
ment strategy
Involvement of the patient in his care (self-monitoring, 
tailoring doses based on a treatment schedule)
Participation along with the medical personnel in the long-
term follow-up of the patient, recording his compliance 
and assessing treatment efficacy.57
C O N C L U S I O N S
Metabolic Syndrome is a particularly common clinical 
-
-
-
-
-
-
-
-
entity characterized by a constellation of various risk factors 
associated with the development of type 2 diabetes mellitus 
and cardiovascular disease. Its hallmarks are dysglycemia, 
hypertension, atherogenic dyslipidemia and central obesity. 
Because MS is a constellation of disease processes, treating 
it requires an integrated approach with the involvement of 
various health care providers. Among them, the nurse can play 
a role of vital significance by actively participating a) in the 
identification of patients with MS and of individuals who are 
at risk to develop it and b) preventing the development of the 
syndrome and its cardiovascular sequelae through the imple-
mentation of a treatment plan featuring an integrated problem 
management approach. This plan should be developed along 
with the patient and has to be based upon patient’s education, 
psychosocial support and close follow-up. The final goal is 
to assure the long-term compliance of the patients with both 
the proposed lifestyle changes and the medical treatment in 
order to achieve a significant reduction in their cardiovascular 
morbidity and mortality.
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